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for BIM, and 203 for TRAV. The mean drug cost (AWP) was
estimated from actual claims as LAT, $301 (95% CI: $293-
$309); BIM: $364 (95% CI: $344-$384); TRAV: $278 (95% CI:
$263-$294). Compared to TRAV, incremental cost effectiveness
ratio of LAT was $0.56 and of BIM was $3.91 per additional
day of uninterrupted therapy. CONCLUSION: Patients do not
remain on ocular prostaglandins longer than six to seven months
before therapy interruption/discontinuation. Patients using LAT
stayed on therapy longer than those using BIM or TRAV and at
a lower cost per additional day of therapy than BIM.
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OBJECTIVE: In comparison to traditional treatment options,
TNF-á inhibitors have shown promise in increasing the clearance
of psoriatic lesions and improving the quality-of-life of patients
with moderate-to-severe psoriasis. They are however associated
with higher costs and side-effects. The study objective was to
compare the cost-effectiveness of TNF-á inhibitors to other pso-
riasis treatment strategies. METHODS: The cost-effectiveness of
ten treatment options from three drug classes- TNF- á inhibitors,
systemic therapies and phototherapy- were evaluated using a
decision analysis model constructed using DATA Treeage. The
probabilities of success were obtained from PASI-75 scores from
published clinical trials. The annual drug costs were obtained
from the Drug Topics Red Book and published clinical trials.
Additional costs associated with treatment, which included
annual pharmacy costs and costs for professional and institutional
services, were obtained from published reports. Incremental cost
effectiveness ratios (ICERs) were calculated for additional cost
divided by incremental PASI-75 values, and were estimated rela-
tive to the drug with the lowest cost. Multiple sensitivity analyses
were performed to determine the robustness of the ﬁndings.
RESULTS: Phototherapy was found to be the most cost-effective
treatment option with an ICER of $16,435.89/PASI-75, relative
to systemic therapy. The most cost-effective TNF-á inhibitor
was inﬂiximab, with an ICER of $15,733/PASI-75, relative to
adalimumab. Inﬂiximab had the highest drug acquisition cost
($21,250) among the 10 treatment strategies. While Goekerman
therapy with a PASI-75 score of 100 had the highest clinical
effectiveness among all the treatment strategies examined, the
more effective TNF-á inhibitor was inﬂiximab, with a PASI-75
score of 82.3. Sensitivity analysis indicated that the results were
affected by the model assumptions. CONCLUSION: Thus,
phototherapy was found to be the more cost-effective treatment
option in this analysis. It is expected that the cost of TNF-á
inhibitors will be lower in the future.
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OBJECTIVE: To determine the cost-effectiveness ratio for quar-
terly injections of Ranizumab in the treatment of Wet AMD, in
Brazilian HMOs scenario. METHODS: A cost-effectiveness
analysis from the private payers perspective, with a time horizon
of ﬁve years were conducted. A decision tree with a Markov
chain considering the probabilities of increasing, decreasing or
maintaining visual acuity (VA) through ﬁve health states based
on VA from 20/40 to 20/400, were performed. Study compara-
tors examined were Ranibizumab (RAN), and Pegaptanib
Sodium (PEG). The clinical aspects regarding beneﬁts (Vision
Year Gained) and probabilities of transition data were extract
from a meta-analysis of randomized clinical trials for the alter-
natives. Treatment costs including adverse events were collected
from private payers reimbursement reference list for profes-
sional, procedures and diagnostics fees and the drugs costs were
collected from manufactures price list. Costs and beneﬁts were
validated by a panel of Brazilian specialists through the Delphi
technique. The discounting rate was 3% for costs and beneﬁts,
the results were converted in US Dollars (R$ 1.8/USD 1.00). A
one-way sensitivity analysis was performed. RESULTS: Patients
using Ranibizumab get more beneﬁts (RAN = 2.66 per vision
year gained; PEG = 2.00 per vision year gained), with the lowest
total cost per treatment (RAN = $29,653 USD; PEG = $30,093
USD) and the lowest cost per QALY (RAN = $11,148 USD/
vision year gained; PEG = $15,046.5 USD/per vision year
gained). Incremental analysis showed Ranibizumab to be the
dominant alternative. Net beneﬁts are greater with Ranibizumab
independent of willingness to pay. The sensitivity analysis on
efﬁciency and costs of Ranibizumab results show that the results
are sensitive to the type of lesion treated. CONCLUSION:
Ranibizumab is the dominant therapy; it offers better beneﬁts in
vision years gained at the lowest cost. The results are sensitive to
the type of lesion treated, showing the need of guidelines to
assure the best resource allocation.
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OBJECTIVE: To determine the incremental cost-effectiveness of
brimonidine/timolol versus dorzolamide/timolol for lowering
intraocular pressure (IOP). METHODS: A cost-effectiveness
analysis was performed using clinical data from 2 investigator-
masked, randomized, 3-month, parallel-comparison studies
performed at 10 sites. In a post-hoc analysis of those patients
receiving monotherapy treatment for IOP lowering (either
brimonidine/timolol or dorzolamide/timolol) for three months,
the proportion of patients at various IOP levels were calculated
and statistically compared. A three month supply of each drug
was calculated based on their respective WAC price and bottle
size (5 ML brimonidine/timolol and 10 ML dorzolamide/
timolol). The incremental cost-effectiveness ratio (ICER) was
calculated as the difference in drug cost divided by the difference
in the percentage of patients meeting the IOP threshold at three
months between brimonidine/timolol and dorzolamide/timolol.
RESULTS: A 3-month supply of brimonidine/timolol and
dorzolamide/timolol were $169.83 and $154.40, respectively
yielding a cost difference of $15.44. The proportion of patients at
lower IOP thresholds was consistantly higher with brimonidine/
timolol compared to dorzolamide/timolol resulting in a statisti-
cally signiﬁcant incremental beneﬁt for the thresholds from less
than 17mmHg to less than 12mmHg. The associated ICER s for
those thresholds range from $55.12–$85.75 per the percentage
of patients reaching the IOP threshold. CONCLUSION: We
calculated brimondine/timolol to be more cost-effective than
dorzolamide/timolol. Given the importance of achieving target
IOP, both cost and effectiveness should be considered when
evaluating combination therapies for glaucoma.
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